Biogen (FRA:IDP) Net Income: €717 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:IDP Biogen Inc FRA:IDP
68 GF Score
Price €178.92
GF Value €170.97
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Biogen Net Income?

Biogen FRA:IDP +0.42% 68 Net Income is €717 Mil as of Jun. 2026. GuruFocus rates FRA:IDP with a GF Score™ of 68/100 and a GF Value™ of €170.97 (Fairly Valued). The stock has 9 warning signs investors should review.

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Biogen's Net Income for the three months ended in Jun. 2026 was €85 Mil. Its Net Income for the trailing twelve months (TTM) ended in Jun. 2026 was €717 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Biogen's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was €0.57.


Biogen  (FRA:IDP) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Biogen's Earnings per Share (Diluted) (EPS) for the quarter that ended in Jun. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Biogen Net Income Related Terms


Biogen Net Income Historical Data

* Premium members only.

The historical data trend for Biogen's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen Net Income Chart

Biogen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,377.15 2,876.27 1,064.73 1,558.75 1,104.14

Biogen Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 550.37 397.46 -41.76 276.37 84.63
FRA:IDP
68GF Score
Biogen Inc FRA:IDP
Net Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogen Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Biogen's Net Income for the fiscal year that ended in Dec. 2025 is calculated as

Net Income(A: Dec. 2025 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=1329.251+-225.114+0+0
=1,104

Biogen's Net Income for the quarter that ended in Jun. 2026 is calculated as

Net Income(Q: Jun. 2026 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=114.923+-30.293+0+0
=85

Net Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €717 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Income →
What does a Net Income of €717 Mil mean?
Biogen (FRA:IDP) has a Net Income of €717 Mil as of Jun. 2026. Net Income is the total earnings after all operating expenses, interest and taxes. View historical data on Biogen and its competitors.
Is Biogen's Net Income too high?
Biogen's current Net Income is €717 Mil. Overall, Biogen has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biogen's Net Income compare to OGN and AMRN?
Biogen's Net Income of €717 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income for a Drug Manufacturers company?
A good Net Income depends on the Drug Manufacturers industry context. However, Net Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income mean?
A high Net Income can signal that a stock is expensive relative to its fundamentals. Net Income is the total earnings after all operating expenses, interest and taxes. View historical data on Biogen and its competitors. Biogen's current Net Income is €717 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Based on GuruFocus' analysis, Biogen (FRA:IDP) is currently considered Fairly Valued. The stock's GF Value™ is €170.97, compared to a current price of €178.92 — trading 4.6% above its estimated fair value. The current Net Income is €717 Mil. Biogen's overall GF Score™ is 68/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income calculated?
Net Income is calculated from a company's financial statements. For Biogen (FRA:IDP), the current Net Income is €717 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogen (FRA:IDP) Overvalued in 2026?

Based on GuruFocus' analysis, Biogen stock appears to be overvalued. The current stock price of €178.92 is trading 4.6% above its estimated GF Value™ of €170.97. GuruFocus considers Biogen to be Fairly Valued.

Key valuation signals for FRA:IDP:

  • Net Income: €717 Mil
  • GF Value™: €170.97 vs. price of €178.92 (4.6% above fair value)
  • GF Score™: 68/100 with 9 warning signs

No single metric tells the full story. See the FRA:IDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biogen Business Description

Address 225 Binney Street, Cambridge, MA, USA, 02142
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
68GF Score

Get the complete analysis for FRA:IDP

Net Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€178.92
Price
€170.97
GF Value